1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,391 | 0,452 | 20:53 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.12. | Cantargia Provides Update on Overall Survival Data from TRIFOUR | 145 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (NASDAQ:CANTA.ST) today announced an update on overall survival results from the Phase 1b/2 TRIFOUR study... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 19.11. | Cantargia Q3 2025: Erster Gewinn durch transformativen Otsuka-Deal | 3 | Investing.com Deutsch | ||
| 19.11. | Cantargia Q3 2025 slides: First-ever profit driven by transformational Otsuka deal | 4 | Investing.com | ||
| 19.11. | Earnings Call Transkript: Cantargia meldet im 3. Quartal 2025 erstmals Umsatzerlöse | 2 | Investing.com Deutsch | ||
| 19.11. | Cantargia Publishes Interim Report for January to September 2025 | 236 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 19, 2025 / Cantargia AB (publ) ("Cantargia") (STO:CANTA) issued its interim report for the period January until September 2025. The report is now available on the... ► Artikel lesen | |
| 12.11. | Cantargia Presents Nomination Committee Ahead of 2026 AGM | 238 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 12, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today provided notification that the Nomination Committee (NC) has been appointed... ► Artikel lesen | |
| 05.11. | Invitation to the Presentation of Cantargia's Interim Report January-September 2025 | 219 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for the first nine months of 2025 on Wednesday... ► Artikel lesen | |
| 23.10. | Cantargia to Participate in Upcoming Conferences | 226 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 23, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that management will participate in the following investor conferences.Stifel... ► Artikel lesen | |
| 02.10. | Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer | 241 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 2, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today announced the appointment of Wolfram Dempke, MD, PhD, MBA as Chief Medical... ► Artikel lesen | |
| 01.10. | Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC | 356 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 30, 2025 / Cantargia (STO:CANTA)High IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while this... ► Artikel lesen | |
| 11.09. | Cantargia Closes the Acquisition of CAN10 by Otsuka | 343 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 11, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that Cantargia and its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) have closed Otsuka's... ► Artikel lesen | |
| 29.08. | Cantargia im Q2 2025: Otsuka-Deal bringt 33 Mio. USD Sofortzahlung bei durchwachsenen klinischen Ergebnissen | 6 | Investing.com Deutsch | ||
| 29.08. | Cantargia Q2 2025 slides: Otsuka deal brings $33M upfront amid mixed clinical results | 2 | Investing.com | ||
| 27.08. | Cantargia Granted Important US Patent for Nadunolimab | 278 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 27, 2025 / Cantargia AB (Publ), Nasdaq Stockholm:CANTA, (Cantargia) today announced that the United States Patent and Trademark Office (USPTO) has granted the patent... ► Artikel lesen | |
| 21.08. | Cantargia: Aktie gibt trotz 630-Mio.-Dollar-Deal mit Otsuka nach | 5 | Investing.com Deutsch | ||
| 21.08. | Cantargia Publishes Half-Year Report 2025 | 366 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 21, 2025 / Cantargia AB (publ) [Nasdaq Stockholm:CANTA] (Cantargia) today issued the interim report for January to June 2025."I started my tenure as interim CEO with... ► Artikel lesen | |
| 18.08. | Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer | 402 | ACCESS Newswire | Dr Steineger's appointment will be effective from September 1.She brings extensive experience as a biotech executive, with a proven track record spanning financial analysis, venture capital, and business... ► Artikel lesen | |
| 12.08. | Invitation to the Presentation of Cantargia's H1 2025 Report | 302 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 12, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first six months of 2025 on Thursday, August... ► Artikel lesen | |
| 17.07. | Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer | 479 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA)Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolerated... ► Artikel lesen | |
| 16.07. | Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer | 395 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 16, 2025 / Cantargia (STO:CANTA)Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival... ► Artikel lesen |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,10 | -0,87 % | Lungenkrebs-Präparat: Studiendaten schieben Biontech an | Die Aktie von BioNTech startet mit frischem Schwung in die Woche und verbucht bis zum Mittag ein Kursplus von gut drei Prozent. Auslöser sind ermutigende Studiendaten zu einem neuen Wirkstoffkandidaten... ► Artikel lesen | |
| EVOTEC | 5,190 | -0,95 % | EQS-News: Evotec SE: Evotec schließt Verkauf von Just - Evotec Biologics Toulouse Standort an Sandoz ab | EQS-News: Evotec SE
/ Schlagwort(e): Vereinbarung
Evotec schließt Verkauf von Just - Evotec Biologics Toulouse Standort an Sandoz ab
08.12.2025 / 07:00 CET/CEST
Für... ► Artikel lesen | |
| QIAGEN | 38,335 | -0,70 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 643,40 | +1,87 % | Regeneron Reports Promising Phase 1/2 Data Of Lynozyfic In Newly Diagnosed Multiple Myeloma | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic (linvoseltamab) in adults with newly diagnosed... ► Artikel lesen | |
| BRAIN BIOTECH | 2,920 | -2,99 % | Der Erfolg von Pharvaris freut Brain Biotech | ||
| SCORPIUS | 0,072 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| CARDIOL THERAPEUTICS | 0,893 | -0,45 % | Cardiol Therapeutics Inc.: New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions | Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,000 | -6,54 % | Burcon NutraScience Corporation: Burcon Highlights Strong Year of Execution and Commercial Momentum in Shareholder Letter | Vancouver, British Columbia--(Newsfile Corp. - December 15, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| CSL | 102,00 | -1,60 % | Down 36% in 2025, should you buy CSL shares today? | ||
| MANNKIND | 4,983 | -1,60 % | MannKind: Leerink hebt Kursziel wegen Tyvaso-DPI-Lizenzeinnahmen auf 9 US-Dollar an | ||
| OCULAR THERAPEUTIX | 12,465 | +0,44 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI in Wet AMD | Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,430 | -2,85 % | Oxford Nanopore Technologies: Appointment of Francis Van Parys as Chief Executive Officer | Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, today announces the appointment of Francis Van Parys as Chief Executive Officer... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,031 | -43,12 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| CODEXIS | 1,451 | +1,68 % | Codexis, Inc.: Codexis Reports Third Quarter 2025 Financial Results | Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif.,... ► Artikel lesen | |
| CORMEDIX | 9,600 | -2,04 % | CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock? |
Das Unternehmen CANTARGIA AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,034 (+9,97 %) liegt der Kurs bei 0,375 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.